Haleon plc (NYSE:HLN – Get Free Report) has earned an average recommendation of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company.
A number of equities research analysts have weighed in on the company. Investec upgraded Haleon from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Morgan Stanley assumed coverage on Haleon in a research report on Wednesday, November 1st. They issued an “overweight” rating for the company.
Haleon Stock Performance
Haleon (NYSE:HLN – Get Free Report) last announced its earnings results on Thursday, November 2nd. The company reported $0.10 earnings per share (EPS) for the quarter. The company had revenue of $3.54 billion for the quarter. Equities analysts expect that Haleon will post 0.44 earnings per share for the current year.
Institutional Investors Weigh In On Haleon
A number of hedge funds and other institutional investors have recently modified their holdings of HLN. Barclays PLC increased its holdings in Haleon by 56.4% during the 2nd quarter. Barclays PLC now owns 3,317 shares of the company’s stock valued at $28,000 after purchasing an additional 1,196 shares during the period. Hollencrest Capital Management lifted its position in Haleon by 21.5% during the 1st quarter. Hollencrest Capital Management now owns 7,114 shares of the company’s stock valued at $58,000 after acquiring an additional 1,258 shares during the period. Farther Finance Advisors LLC boosted its position in shares of Haleon by 79.3% in the 2nd quarter. Farther Finance Advisors LLC now owns 2,986 shares of the company’s stock worth $25,000 after purchasing an additional 1,321 shares in the last quarter. Apollon Wealth Management LLC boosted its holdings in Haleon by 11.0% in the first quarter. Apollon Wealth Management LLC now owns 13,404 shares of the company’s stock worth $109,000 after acquiring an additional 1,332 shares in the last quarter. Finally, Financial Advocates Investment Management boosted its stake in Haleon by 10.5% in the 3rd quarter. Financial Advocates Investment Management now owns 14,849 shares of the company’s stock worth $124,000 after purchasing an additional 1,408 shares in the last quarter. Institutional investors own 6.67% of the company’s stock.
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements.
- Five stocks we like better than Haleon
- Where to Find Earnings Call Transcripts
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- What is ChatGPT Stock? How to Invest in It
- MarketBeat Week in Review – 11/13 – 11/17
- How to Invest in Fertilizer
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.